Why Is CANDEL THERAPEUTICS (CADL) Stock Moving Today?

CADL stock is moving higher today amid a recent price target upgrade from BofA. The stock closed up 4.2% as the firm raised its price target to $12 from $9. The move reflects renewed optimism about the company's pipeline despite ongoing earnings challenges.

What Happened

BofA Securities increased its price target for Candel Therapeutics to $12 from $9, signaling a more positive outlook. The firm maintains a neutral stance on the stock. This follows a recent update on the company's clinical development, with Candel Therapeutics initiating its pivotal Phase 3 AURORA study of aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab in participants with metastatic non-squamous non-small cell lung cancer. The stock has been volatile in recent months, having traded between $4.35 and $11.95 over the past 52 weeks.

What The Data Shows

The stock has printed two fresh 52-week highs on August 17. Recent insider transactions show two sales totaling $306K in the last 90 days, with the most recent filing on July 1. The company remains unprofitable, with a trailing twelve-month EPS of -0.97 and a market cap of $775.2M. Volume has not been reported as unusually high, but the stock’s recent price action suggests increased investor attention.

What To Watch

Candel Therapeutics is not scheduled to report earnings in the near term. Investors should monitor the breadth of coverage as additional analyst ratings could influence the stock’s trajectory.